CEO Andrew Dudum said Hims is building "an entire health ecosystem" rather than serving as a solution for a single health ...

Key Points Interested in Hims & Hers Health, Inc.? Here are five stocks we like better. Hims & Hers Health plans to acquire ...

Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 ...

Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Her ...

Hims & Hers built massive weight-loss markets using telehealth. Peptides, if authorized by the FDA, stand to become a major ...

Hims & Hers Health added more than ~7% in the early morning hours on Wednesday after David Wells, a director of the ...

Hims & Hers Health is now offering generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering. Personalized treatment pl ...

Hims is dealing with margin compression. While Hims management raised its revenue outlook for the year, it significantly lowered its adjusted EBITDA guidance. It now expects reven ...

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest ...

NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss ⁠drug ⁠business, is promising it can diversify away from its ⁠reliance on compounded GLP-1 sales in the U ...

Hims offers convenient, discreet prescription hair loss treatments for men. Learn if it's right for you and what to expect.